Fig. 5. Long-term in vivo treatment with venetoclax following bone marrow transplantation does not affect the relative proportions of any T cell subset.

A Schematic of transplant procedure where recipient CD45.1⁺ mice were lethally irradiated on day -1 and were transplanted with 2 × 10⁶T cell-depleted (TCD) bone marrow from FOXP3-IRES-GFP (CD45.2⁺) donors on day 0. Daily oral gavage treatment with 25 or 50 mg/kg venetoclax was initiated on day +1 and continued until day +28 post-transplant. B Percentage (top) and absolute numbers (bottom) of CD8⁺ T cells, CD4⁺ T cells, and Tregs, shown as subsets of total CD4⁺ T cells isolated from animals 1, 2, and 3 months post-transplant. C Proportions of naive (CD44^lowCD62L^high), effector memory (CD44^highCD62L^low), and central memory (CD44^highCD62L^high) T cells, shown as percentages (top) and absolute numbers (bottom). N.A. = the low number of Tregs one-month post-transplant precluded their thorough analysis at this time. n = 5 mice/group for the 1 and 2 month timepoints and n = 3 for the 3 month timepoint. Data represented as means ± SEM of two independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.